The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group Members, Thom, T., Haase, N., Rosamond, W., Howard, V. J., Rumsfeld, J., Manolio, T., Zheng, Z.-J., Flegal, K., O’Donnell, C., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.171600 · Cited by 3,451
PERZBORN, E., STRASSBURGER, J., WILMEN, A., POHLMANN, J., ROEHRIG, S., SCHLEMMER, K.-H., & STRAUB, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01166.x · Cited by 590
Pinto, D. J. P., Orwat, M. J., Koch, S., Rossi, K. A., Alexander, R. S., Smallwood, A., Wong, P. C., Rendina, A. R., Luettgen, J. M., Knabb, R. M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070245n · Cited by 402
Self-citationLASSEN, M. R., DAVIDSON, B. L., GALLUS, A., PINEO, G., ANSELL, J., & DEITCHMAN, D. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02764.x · Cited by 374
GEROTZIAFAS, G. T., ELALAMY, I., DEPASSE, F., PERZBORN, E., & SAMAMA, M. M. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02429.x · Cited by 159
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent
Walenga, J. M., Jeske, W. P., Frapaise, F.-X., Bick, R. L., Fareed, J., & Samama, M. M. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.3.397 · Cited by 121
Oral direct thrombin inhibitors in clinical development
Gustafsson, D. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01225.x · Cited by 79
Wong, P. C., Quan, M. L. C., Earl J., C., Watson, C. A., Wexler, R. R., & Knabb, R. M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35299-1 · Cited by 73
Self-citationOrally Active Isoxazoline GPIIb/IIIa Antagonists
Mousa, S. A., & Wityak, J. (1998) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.1998.tb00344.x · Cited by 32
Cited by
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62125-5 · Cited by 777
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Portman, R. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810773 · Cited by 695
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 612
Self-citation
Metadata
- Authors
- WONG, P. C., CRAIN, E. J., XIN, B., WEXLER, R. R., LAM, P. Y. S., PINTO, D. J., LUETTGEN, J. M., & KNABB, R. M.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 6
- Issue
- 5
- Pages
- 820-829
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W1878559559
- Cited by
- 300
- References
- 9
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. https://app.cochat.ai/papers/10.1111/j.1538-7836.2008.02939.x
- The paper
- WONG, P. C., CRAIN, E. J., XIN, B., WEXLER, R. R., LAM, P. Y. S., PINTO, D. J., LUETTGEN, J. M., & KNABB, R. M. (2008). Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis. https://doi.org/10.1111/j.1538-7836.2008.02939.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.